The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates there will be over 35 million new ...

FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates ...

In another controversial move, Health and Human Services Secretary Robert F. Kennedy Jr. has abruptly fired all 17 members of ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

Bullish option flow detected in Pfizer (PFE) with 50,489 calls trading, 2x expected, and implied vol increasing over 2 points to 26.82%. 6/13 ...

ASCO Data Shows New Therapy Delays Breast Cancer Progression and May Improve Quality of Life for Women with Hormone ...

Bank of America Securities analyst Tim Anderson maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $27.00. The company’s shares closed ...

Arvinas, Inc. (NASDAQ: ARVN) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

Vepdegestrant has been recognized with fast track designation by the FDA and is being co-developed by Arvinas and Pfizer. The ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...